Navigation Links
Dendreon Announces Pricing of $540 Million Convertible Senior Notes Due 2016
Date:1/14/2011

net proceeds of the offering of the Notes to fund the continued investment in and expansion of its manufacturing facilities, including the construction of a new immunotherapy manufacturing facility in Europe and the expenses associated with increasing capacity at its existing Morris Plains, New Jersey, Atlanta, Georgia and Orange County, California facilities; cover expenses in connection with pursuing non-U.S. marketing approvals for PROVENGE® (sipuleucel-T); fund new clinical trials for PROVENGE and other product candidates; finance its marketing and awareness efforts for PROVENGE; fund the ongoing hiring of additional manufacturing, sales and marketing, quality, research and development and other personnel to support PROVENGE and its other product candidates; fund additional investment in information technology infrastructure and product support systems; for third-party contract supply costs; and for general corporate purposes, including working capital.  Dendreon may also use a portion of the net proceeds to acquire strategic assets, although Dendreon currently has no agreements or commitments to do so.

In connection with the offering of the Notes, the underwriter expects to distribute in an offering registered under the Securities Act 1,787,100 outstanding shares of Common Stock (subject to minor adjustments related to the allocation of the Notes) to facilitate the hedging of the Notes by buyers of the Notes.  Dendreon has been advised by the underwriter that it purchased the shares of Common Stock from buyers of the Notes in connection with, and contingent on the closing of, the Notes offering, with a view to initially offer the shares of Common Stock to the public at a price of $35.70 per share and to subsequently offer the shares of Common Stock in one or more transactions on The NASDAQ Global Select Market, in the over-the-counter market, through negotiated transactions or otherwise at the market prices prevailing at the time of the s
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
3. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
4. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
5. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
6. Dendreon Reports Third Quarter 2008 Financial Results
7. Dendreon Announces Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
8. Dendreon Announces Webcast Presentation at Eleventh Annual BIO CEO & Investor Conference
9. Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
10. Dendreon Announces Data on PROVENGE Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer
11. Dendreon Announces Data Presentations and Webcast at AUA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 Astra Nova Training ... consultancy and pharma training services, and the ... , a non-profit integrating the expertise and investments ... a global system for clinical trials, are pleased ... the expertise of industry professionals through improved and ...
(Date:7/22/2014)... WASHINGTON D.C., June 22, 2014 Even within a phylum ... fly is distinguished among other arthropods for its cruelty -- ... and Central America, the fly is a most predatory sort ... male cricket, deposits a smear of larvae, and leaves its ... inside out. , None of this would be possible ...
(Date:7/22/2014)... mechanical engineering at the University of Texas at Dallas, ... North Texas section of the American Society of Mechanical ... in 158 countries who develop engineering standards and training. ... benefiting the world. , ASME recognized Baughn earlier this ... banquet. Baughn retired as an engineering fellow in 2012 ...
(Date:7/22/2014)... July 22, 2014 CTD Holdings, Inc. ... pharmaceutical, medical device, cosmetics, and other markets, announced today ... a group of qualified private investors led by Novit ... , The transaction involved the signing of a ... shares of Common Stock at a price per share ...
Breaking Biology Technology:Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 2Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 3Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4UT Dallas professor receives Engineer of the Year award 2CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3
... N.Y. Whoever penned the old adage "a watched pot ... a pot lined with copper nanorods. , A new study ... an invisible layer of the nanomaterials to the bottom of ... required to bring water to boil. This increase in efficiency ...
... of Standards and Technology (NIST) have developed a ... magnetic materials such as nickel or nickel-iron alloys ... process, described in a recent paper,* could enable ... devices. , The NIST team also demonstrated that ...
... Inc.,("Dragon Pharma" or the "Company" TSX: DDD; OTCBB: ... announced the results,of the Annual Shareholders Meeting held ... were 48,663,865 shares equaling 69.81% of the outstanding ... following,eight persons to serve as members of the ...
Cached Biology Technology:On the boil: New nano technique significantly boosts boiling efficiency 2On the boil: New nano technique significantly boosts boiling efficiency 3New process creates 3-D nanostructures with magnetic materials 2
(Date:7/22/2014)... In contrast to their negative reputation as disease ... and evolutionary functions that help to shape the ... new report by the American Academy of Microbiology. ... influence all life forms on the planet, from ... and driving major speciation events," states Marilyn Roossinck ...
(Date:7/22/2014)... N.C. In a cost-effectiveness analysis of commercial diet ... drug Qsymia showed the best value for the money. ... but was also the most expensive option tested, according ... Medical School. , The findings, published in the June ... information on the health and weight-loss benefits per dollar ...
(Date:7/22/2014)... China July 22, 2014 BGI Tech ... BGI, the world,s largest genomics organization, announced today ... exome sequencing service based on Complete Genomics, industry-leading ... analysis and SNP validation, and is available at ... Complete Genomics, highly regarded in the industry for ...
Breaking Biology News(10 mins):Report on viruses looks beyond disease 2Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3BGI Tech launches human whole exome sequencing service on complete genomics' advanced platform 2
... has always depended on harvesting from nature for food ... for technological ideas. Indeed, the guiding principle behind ... evolutionary process has already performed innumerable experiments over many ... Cheryl Hayashi will give a free public ...
... a stubby tail: an odd-looking mouse discovered through a U.S. government ... and an extra set of ribs in its neck and ... at the University of California, San Francisco has now spilled the ... have uncovered a new wrinkle in the genetic code an ...
... the Max Planck Society (MPG; President Peter ,Gruss) signed ... collaboration by ,establishing a joint research center for systems ... systematic understanding of biological systems from a chemistry perspective. ... together the RIKEN Advanced Science Institute,s ,natural chemical compounds ...
Cached Biology News:How nature's best ideas inspire innovative new technologies 2Mutant mouse reveals new wrinkle in genetic code, say UCSF scientists 2Mutant mouse reveals new wrinkle in genetic code, say UCSF scientists 3